Clin2
NCT06057519Possibly a fitRecruiting

Optimized rifampicin dosing for TB

Tuberculosis, Pulmonary

Part of Infections, Lungs & breathing clinical trials.

This trial tests whether higher or standard doses of the antibiotic rifampicin work better for treating pulmonary tuberculosis (a lung infection). You may benefit if you are starting TB treatment and have not had a bad reaction to rifampicin before.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
164 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You have been diagnosed with pulmonary tuberculosis (TB in the lungs).
  • You have not had an allergic reaction to rifampicin in the past.
  • You have not been treated for TB for more than 4 weeks already.
  • You are not pregnant, breastfeeding, or planning to become pregnant during the study.
  • You do not have a rifampicin-resistant strain of TB.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05401071Recruiting· Phase 2/Phase 3
Test shorter rifapentine-based treatment for drug-sensitive TB

This trial studies whether a rifapentine-based TB regimen can work just as well while shortening treatment time. It’s for people with rifampicin-sensitive, smear-positive lung tuberculosis.

Guiyang, Guizhou
NCT04485156Not yet recruiting· Phase 3
Shorter treatment for drug-sensitive lung tuberculosis using higher rifampicin

This trial tests whether you can take a shorter course of standard treatment for drug-sensitive pulmonary (lung) tuberculosis by using a higher dose of rifampicin. It may help some people finish treatment sooner, while doctors track how well the infection clears.

Seoul
NCT06585358Recruiting
Precision Dosing for Pulmonary Tuberculosis

This trial tests a personalized approach to dosing the TB medicine rifampin. By using a computer model based on your individual factors, doctors hope to find the right dose for you, which may improve treatment outcomes.

Linköping
NCT06526039Not yet recruiting· Phase 3
Shorter treatment for rifampicin-resistant TB sensitive to isoniazid

This trial tests a shorter treatment for TB that is resistant to the drug rifampicin but still sensitive to isoniazid. It may help people finish treatment sooner and with fewer side effects.

NCT06441006Recruiting· Phase 2/Phase 3
Personalized treatment for rifampicin-resistant TB

This trial tests a personalized treatment approach for people with rifampicin-resistant TB that is still sensitive to fluoroquinolones. It aims to find the best combination of medicines based on your specific TB profile.

Ulaanbaatar
NCT06253715Recruiting· Phase 3
Shorter TB treatment for children

This trial tests a shorter treatment for children with tuberculosis (TB) that is not drug-resistant. It aims to find out if a shorter regimen works as well as the standard longer one, making treatment easier for children and their families.

Chennai

Hear when a new Tuberculosis, Pulmonary trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.